Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Next Previous
Trial Profile

A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Brain cancer; Diffuse intrinsic pontine glioma; Glioma
  • Focus Adverse reactions
  • Sponsors Alaunos Therapeutics

    • Most Recent Events

    • 03 Nov 2021 Status changed from recruiting to discontinued as per sponsor decision due to slow accrual.
    • 19 Nov 2020 According to a ZIOPHARM Oncology media release, results from the first patient in this study were presented by Stewart Goldman (M.D., Division Head Hematology-Oncology, Neuro-Oncology and Stem Cell Transplantation at Lurie Childrens Hospital and investigator in the study) at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting.
    • 19 Nov 2020 Results from the first patient (NCT03330197) in the study was presented in a ZIOPHARM Oncology media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top